Literature DB >> 3750372

Factors influencing simultaneous concentrations of total and free carbamazepine and carbamazepine-10, 11-epoxide in serum of children with epilepsy.

A A Elyas, P N Patsalos, O A Agbato, E M Brett, P T Lascelles.   

Abstract

Various factors that may influence the simultaneous concentration of total and free carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZ-E) in serum of 68 children (mean age 11.8 +/- 4.5 years) with epilepsy were assessed. Separation of free and bound drug fractions was achieved by ultrafiltration, and CBZ and CBZ-E concentrations were determined using a sensitive high pressure liquid chromatographic technique. Thirty children were on CBZ monotherapy. Both total CBZ and CBZ-E serum concentrations correlated significantly with their respective free serum concentrations. CBZ was 81 +/- 3% and CBZ-E 63 +/- 9% bound. There was no correlation between the CBZ dose and either CBZ total or free serum concentrations. A statistically significant correlation was, however, observed between CBZ dose and simultaneous CBZ-E total and free concentrations. CBZ total and free concentrations correlated significantly with those of total CBZ-E. A significant negative correlation was observed between age and total (r = -0.49, p less than 0.01) and free (r = -0.43, p less than 0.025) CBZ-E/CBZ ratios. Concomitant drug therapy (phenytoin, phenobarbitone, and sodium valproate) significantly elevated CBZ-E/CBZ ratios.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3750372     DOI: 10.1097/00007691-198609000-00009

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  8 in total

1.  Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia.

Authors:  P N Patsalos; A A Elyas; J M Zakrzewska
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

Review 3.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

4.  Carbamazepine clearance in paediatric epilepsy patients. Influence of body mass, dose, sex and co-medication.

Authors:  B Summers; R S Summers
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

5.  Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children.

Authors:  R Hartley; W I Forsythe; B McLain; P C Ng; M D Lucock
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

6.  Childhood Epilepsy : Current Therapeutic Recommendations.

Authors:  J T Gilman; M Duchowny
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

7.  A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients.

Authors:  P N Patsalos
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.